ALCAM and neoplasm: The CD166-targeted agent that we developed in this study showed higher tumor uptake (11.1 ± 2.2 %ID/g, 24 h) and tumor-to-muscle ratios (48.9 ± 5.03, 48 h) in CRCSCs xenograft.